Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: Results of five patients

Bone Marrow Transplantation

Volumn 30, Issue 2, 2002, Pages 95-102

  Bay, J O ^a   Fleury, J ^a   Choufi, B ^a   Tournilhac, O ^b   Vincent, C ^a   Bailly, C ^a   Dauplat, J ^a   Viens, P ^c   Faucher, C ^c   Blaise, D ^c  

^a CENTRE JEAN PERRIN   (France)

^b HÔTEL DIEU   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Allogeneic transplantation; Graft versus ovarian cancer; Non myeloablative regimen; Ovarian cancer

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; BUSULFAN; CA 125 ANTIGEN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MESNA; METHYLPREDNISOLONE; PACLITAXEL; PENTAMIDINE; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER REGRESSION; CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DONOR; DOSE RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INFECTION; INFECTION SENSITIVITY; KIDNEY CARCINOMA; LYMPHOCYTE TRANSFUSION; OVARY CARCINOMA; PRIORITY JOURNAL; SIBLING; SOLID TUMOR; STEM CELL TRANSPLANTATION; TIME; TUMOR VOLUME; ALLOTRANSPLANTATION; CASE REPORT; CLINICAL TRIAL; GRAFT SURVIVAL; HISTOCOMPATIBILITY; ISOGRAFT; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PILOT STUDY; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRAFT SURVIVAL; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MIDDLE AGED; OVARIAN NEOPLASMS; PILOT PROJECTS; SURVIVAL RATE; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC;

EID: 0036053789     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703609     Document Type: Article

References (44)

1. Chemotherapy in ovarian cancer. New approaches to treatment
2. Management of ovarian carcinoma. Current concepts and future prospects
3. Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy
4. Female genital tract cancer
5. Chemotherapy in advanced ovarian carcinoma: Current standards of care based on randomized trials
6. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer
7. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
8. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
9. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
10. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: 24-hour versus 7-day infusion
11. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma
12. Bone-marrow transplantation
13. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
14. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
15. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia
16. Influence of chronic graft-versus-disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
17. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
18. Graft-versus-leukemia reactions after bone marrow transplantation
19. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias
20. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion
21. Long-term follow-up of T-cell depletion for bone marrow transplantation
22. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
23. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
24. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
25. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
26. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect
27. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia
28. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
29. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
30. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
31. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer
32. Management of acute graft-versus-host disease
33. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study
34. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
35. Bone marrow transplantation
36. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells
37. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immuno-suppression after marrow transplant
38. Nonmyeloablative transplants: Preclinical and clinical results
39. Nonablative allogeneic hematopoietic stem cell transplantation
40. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome
41. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation
42. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients
43. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
44. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia